HPP 593

Drug Profile

HPP 593

Alternative Names: HPP593

Latest Information Update: 01 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Developer High Point Pharmaceuticals; vTv Therapeutics LLC
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscle fatigue
  • No development reported Diabetes mellitus; Dyslipidaemias

Most Recent Events

  • 19 Jan 2016 No development reported - Phase-I for Diabetes mellitus in USA (PO)
  • 19 Jan 2016 No development reported - Phase-I for Dyslipidaemias in USA (PO)
  • 19 Jan 2016 Phase-I clinical trials in Muscle fatigue (Prevention) in USA (unspecified route) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top